C4 Therapeutics (CCCC) EBT Margin (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly EBT Margin of 446.13% for Q1 2026, down 8247.0% year-over-year from 5.48% in Q1 2025, and down 141.32% quarter-over-quarter from 184.87% in Q4 2025.
Powered by 
Analysis
C4 Therapeutics (CCCC) EBT Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' EBT Margin history runs 8 years deep, the most recent figure standing at 446.13% for Q1 2026.
- In Q1 2026, EBT Margin fell 8247.0% year-over-year to 446.13%; the TTM figure through Mar 2026 stood at 304.06% (down 4478.0% YoY), while the FY2025 annual figure was 291.74%, up 385.0% from the prior year.
- EBT Margin for Q1 2026 stood at 446.13%, down from 184.87% in the prior quarter.
- The five-year high for EBT Margin was 147.56% in Q2 2024, with the low at 1348.42% in Q2 2023.
- The 5-year median for EBT Margin is 446.13% (2026), against an average of 604.45%.
- The sharpest annual moves came in 2022 and 2024: EBT Margin tumbled 122492 bps in 2022, then jumped 120086 bps in 2024.
- C4 Therapeutics' EBT Margin stood at 1302.91% in 2022, then rose by 19 bps to 1057.25% in 2023, then soared by 37 bps to 665.29% in 2024, then surged by 72 bps to 184.87% in 2025, then plunged by 141 bps to 446.13% in 2026.
- Business Quant data shows CCCC's EBT Margin at 446.13% in Q1 2026, 184.87% in Q4 2025, and 286.43% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | C4 Therapeutics | 492.73 Mn | 239.06 Mn | - | -355.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -355.90% |
| Mar 31, 2026 | -408.47% |
| Dec 31, 2025 | -184.87% |
| Sep 30, 2025 | -286.43% |
| Jun 30, 2025 | -402.60% |
| Mar 31, 2025 | -363.66% |
| Dec 31, 2024 | -665.29% |
| Sep 30, 2024 | -160.57% |
| Jun 30, 2024 | -147.56% |
| Mar 31, 2024 | -933.23% |
| Dec 31, 2023 | -1,057.25% |
| Sep 30, 2023 | -235.13% |
| Jun 30, 2023 | -1,348.42% |
| Mar 31, 2023 | -925.25% |
| Dec 31, 2022 | -1,302.91% |
| Sep 30, 2022 | -473.17% |
| Jun 30, 2022 | -194.29% |
| Mar 31, 2022 | -413.12% |
| Dec 31, 2021 | -77.99% |
| Sep 30, 2021 | -290.39% |